Reviva (RVPH) CEO receives 150,075 stock option grants under 2020 plan
Rhea-AI Filing Summary
REVIVA PHARMACEUTICALS HOLDINGS, INC. President and CEO Laxminarayan Bhat reported receiving two stock option awards under the company’s 2020 Equity Incentive Plan. The grants cover a total of 150,075 options to buy common stock at an exercise price of $1.87 per share, expiring on March 17, 2036.
One option for 109,150 shares is held directly and another for 40,925 shares is held indirectly through his spouse. For the direct grant, 34,110 options vest immediately and 75,040 vest in equal monthly installments from April 2026 to December 2028. For the spouse-held grant, 12,789 options vest immediately and 28,136 vest on the same monthly schedule. These are compensation-related awards, not open‑market share purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Bhat Laxminarayan
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 109,150 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) | 40,925 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 109,150 shares (Direct);
Stock Option (right to buy) — 40,925 shares (Indirect, By Spouse)
Footnotes (2)
- F1. This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.
- F2. This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.
FAQ
What did RVPH President and CEO Laxminarayan Bhat report on this Form 4?
He reported two stock option awards under Reviva’s 2020 Equity Incentive Plan. The grants provide rights to acquire a total of 150,075 shares of common stock at a fixed exercise price, with specified vesting schedules and a long-dated expiration in 2036.
How many stock options were granted to the RVPH CEO and his spouse?
The filing shows 150,075 stock options in total. Bhat received 109,150 options held directly, while 40,925 options are held indirectly through his spouse. Each grant has its own immediate and time-based vesting structure tied to the 2020 Equity Incentive Plan.
What are the vesting terms of the RVPH CEO’s new option awards?
For the 109,150-share grant, 34,110 options vest immediately and 75,040 vest monthly from April 2026 to December 2028. For the 40,925-share spouse-held grant, 12,789 vest immediately and 28,136 vest monthly over the same period, all under the 2020 Equity Incentive Plan.
What is the exercise price and expiration date of the RVPH CEO’s options?
Both grants have an exercise price of $1.87 per share, based on Reviva’s common stock closing price on the March 18, 2026 grant date. The options expire on March 17, 2036, giving a 10-year term consistent with typical equity incentive awards.
Were these RVPH CEO transactions open-market purchases or sales of stock?
No, the Form 4 shows grant or award acquisitions of stock options, coded “A.” These are compensation-related option grants, not open-market buying or selling of existing shares. No purchase or sale price is reported, only the option exercise price and vesting terms.
How are the spouse-held RVPH options treated in the Form 4 filing?
The 40,925-share option grant is reported as indirect ownership “By Spouse”. It vests with the same immediate and monthly schedule and the same $1.87 exercise price and 2036 expiration. The filing attributes these options as indirectly owned through the spouse.
AI-generated analysis. How Rhea-AI works. Not financial advice.
